Targeting ALDH bright human carcinoma-initiating cells with ALDH1A1-specific CD8 + T cells

Clinical Cancer Research

Volumn 17, Issue 19, 2011, Pages 6174-6184

  Visus, Carmen ^a,b   Wang, Yangyang ^a,b   Lozano Leon, Antonio ^a,b   Ferris, Robert L ^a,b   Silver, Susan ^c   Szczepanski, Miroslaw J ^a,b,e   Brand, Randall E ^b   Ferrone, Cristina R ^d   Whiteside, Theresa L ^a,b   Ferrone, Soldano ^a,b   DeLeo, Albert B ^a,b   Wang, Xinhui ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Special Pathogens Laboratory   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 1A1; ALDEHYDE DEHYDROGENASE 1A1[88-96]; HLA ANTIGEN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CARCINOMA INITIATING CELL; CD8+ T LYMPHOCYTE; CELL ISOLATION; CONTROLLED STUDY; DRUG TARGETING; FLOW CYTOMETRY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT;

ALDEHYDE DEHYDROGENASE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; ISOENZYMES; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOPLASTIC STEM CELLS; RETINAL DEHYDROGENASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053542413     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1111     Document Type: Article

References (41)

1. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells - perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006;66: 9339-44. (Pubitemid 44623625)
2. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007;23:675-99.
3. Dick JE. Stem cell concepts renew cancer research. Blood 2008;112: 4793-807.
4. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68.
5. Visvader JE. Cells of origin in cancer. Nature 2011;469:314-22.
6. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-67. (Pubitemid 350056407)
7. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009;69:1302-13.
8. Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 2010;102: 340-51.
9. Boonyaratanakornkit JB, Yue L, Strachan LR, Scalapino KJ, LeBoit PE, Lu Y, et al. Selection of tumorigenic melanoma cells using ALDH. J Invest Dermatol 2010;130:2799-808.
10. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009;69:3382-9.
11. Chen YC, Chen YW, Hsu HS, Tseng LM, Huang PI, Lu KH, et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun 2009;385:307-13.
12. Clay MR, Tabor M, Owen JH, Carey TE, Bradford CR, Wolf GT, et al. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck 2010;32:1195-201.
13. Liu S, Wicha MS. Targeting breast cancer stem cells. J Clin Oncol 2010;28:4006-12.
14. + T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res 2007;67: 10538-45.
15. Marchitti SA, Brocker C, Stagos D, Vasiliou V. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol 2008;4:697-720. (Pubitemid 352003194)
16. + cytotoxic lymphocytes for adoptive immunotherapy. J Immunol 2007;179:4910-8.
17. Suhoski MM, Golovina TN, Aqui NA, Tai VC, Varela-Rohena A, Milone MC, et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther 2007;15:981-8. (Pubitemid 46621657)
18. Sluijter BJ, van den Hout MF, Stam AG, Lougheed SM, Suhoski MM, van den Eer twegh AJ, et al. 4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8(+) T cells from melanoma sentinel lymph nodes. Clin Immunol 2010;137: 221-33.
19. Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, et al. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 1978;14:9-20. (Pubitemid 8340429)
20. Lampson LA, Levy R. Two populations of Ia-like molecules on a human B cell line. J Immunol 1980;125:293-9. (Pubitemid 10040437)
21. Tsujisaki M, Sakaguchi K, Igarashi M, Richiardi P, Perosa F, Ferrone S. Fine specificity and idiotype diversity of the murine anti-HLA-A2, A28 monoclonal antibodies CR11-351 and KS1. Transplantation 1988;45: 632-9. (Pubitemid 18086575)
22. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986;137: 2299-306. (Pubitemid 16020728)
23. Stam NJ, Vroom TM, Peters PJ, Pastoors EB, Ploegh HL. HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in Western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol 1990;2: 113-25. (Pubitemid 20050409)
24. + T cells specific for the wild-type sequence p53264-272 peptide in the circulation of patients with head and neck cancer. Cancer Res 2002;62:3521-9.
25. Carlsson G, Fullberg B, Haftstrom L. Estimation of liver tumor volume using different formulas-an experimental study in rats. J Cancer Res Clin Oncol 1983;105:20-3. (Pubitemid 13194363)
26. Katre NV, Knauf MJ, Laird WJ. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc Natl Acad Sci U S A 1987;84:1487-91. (Pubitemid 17066715)
27. Hendzel MJ, Wei Y, Mancini MA, van Hooser A, Ranalli T, Brinkley BR, et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997;106:348-60. (Pubitemid 27510848)
28. Choi HS, Choi BY, Cho YY, Mizuno H, Kang BS, Bode AM, et al. Phosphorylation of histone H3 at serine 10 is indispensable for neoplastic cell transformation. Cancer Res 2005;65:5818-27. (Pubitemid 40911186)
29. Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, et al. CSPG4 as new target for antibody-based immunotherapy of triple negative breast cancer. J Natl Cancer Inst 2010;102:1496-512.
30. Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, et al. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 2011;29:32-45.
31. Natali PG, Bigotti A, Nicotra MR, Viora M, Manfredi D, Ferrone S. Distribution of human class I (HLA-A, B, C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res 1984;44:4679-87. (Pubitemid 14008799)
32. Sung CH, Hu CP, Hsu HC, Ng AK, Chou CK, Ting LP, et al. Expression of class I and class II major histocompatibility antigens on human hepatocellular carcinoma. J Clin Invest 1989;83:421-9. (Pubitemid 19061160)
33. Kurokohchi K, Carrington M, Mann DL, Simonis TB, Alexander-Miller MA, Feinstone SM, et al. Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma. Hepatology 1996;23:1181-8. (Pubitemid 26137065)
34. + cytolytic T cells. Cancer Res 2009;69:8886-93.
35. Di Tomaso T, Mazzoleni S, Wang E, Sovena G, Clavenna D, Franzin A, et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res 2010;16:800-13.
36. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
37. Lopez-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB, et al. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 2006;176:3402-9. (Pubitemid 43363987)
38. Inoda S, Hirohashi Y, Torigoe T, Morita R, Takahashi A, Asanuma H, et al. Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells. Am J Pathol 2011;178:1805-13.
39. Rasper M, Schäfer A, Piontek G, Teufel J, Brockhoff G, Ringel F, et al. Aldehyde dehydrogenase 1 positive glioblastoma cells show brain tumor stem cell capacity. Neuro Oncol 2010;12:1024-33.
40. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007;117:1466-76. (Pubitemid 46871329)
41. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009;21:233-40.